U.S., Nov. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07938645) titled 'PARP Inhibition for Biliary Tract Cancer With Mutations in Core and Non-Core Homologous Recombination Deficiency Genes' on Oct. 30.
Brief Summary: The IMMUPARP study is an open-label, multicenter phase II trial investigating maintenance therapy with olaparib plus durvalumab in patients with platinum-sensitive advanced biliary tract cancer harboring homologous recombination deficiency (HRD)-associated gene alterations after response or stable disease on first-line chemoimmunotherapy.
Study Start Date: Jan., 2027
Study Type: INTERVENTIONAL
Condition:
Biliary Tract Cancer (BTC)
Intervention:
DRUG: Olaparib + durvalumab
Experimen...